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Abstract
Introduction: The intravitreal injection of antibiotics remains the mainstay of therapy for postoperative
endophthalmitis. Bacterial resistance, however, is still a pitfall in achieving an adequate response to treatment.
Quinupristin/dalfopristin might be a feasible therapeutic option in these cases.
Case presentation: A 55-year-old Hispanic man had endophthalmitis secondary to Staphylococcus aureus in his
right eye and was treated with intravitreal 0.4 mg/0.1 ml quinupristin/dalfopristin injection. Inflammation and pain
remission were observed at four days after injection. The final best-corrected visual acuity was 20/40.
Conclusion: Although vancomycin remains the first-line intravitreal antibiotic therapy against infectious
endophthalmitis caused by Gram-positive bacteria, quinupristin/dalfopristin exhibits similar efficacy and is
theoretically more active against vancomycin-resistant strains, with no apparent retinal toxicity.
Introduction
Postoperative endophthalmitis has been a major and
dreaded complication in all types of eye surgery. Several
measures have been used for its prevention, such as
aseptic techniques and topical prophylactic antibiotics.
Although these measures have resulted in very low
endophthalmitis incidence [1], they have not been able
to eliminate it completely.
Once infection is identified, the mainstay of therapy
has been the intravitreal injection of antibiotics [2]. The
concomitant use of pars plana vitrectomy and steroids
has also been recommended [3] in some cases.
The most common bacterial etiology of the disease
involves Gram-positive bacteria, especially Staphylococci.
Vancomycin, a glucopeptide antibiotic, has shown ade-
quate activity against this type of bacteria [4].
Nonetheless, as with all kinds of antibiotics, resistance
that could preclude a favorable outcome in these
patients may emerge [5].
Quinupristin/dalfopristin (Q/D), a recently developed
streptogramin antibiotic, has shown better activity
against vancomycin-resistant strains of staphylococci [6].
T h ep u r p o s eo ft h i sr e p o r ti st od e s c r i b eac a s ei n
which intravitreal quinupristin/dalfopristin injection in
endophthalmitis due to Staphylococcus sp. resulted in
remission of the infection.
Case presentation
A 55-year-old Hispanic man, in whom non-complicated
phacoemulsification surgery had been performed in the
right eye, exhibited a sudden decrease in visual acuity,
intense pain, and marked red eye two days later.
The visual acuity was hand movement, with an intense
ciliary reaction, hypopion, and moderate corneal edema
(Figure 1). A diagnosis of endophthalmitis was then
made.
B-scan echography showed increased intravitreal
echoes due to the severe inflammatory reaction. A pars
plana vitrectomy was performed, and a vitreous biopsy
specimen was obtained. A combination of quinupris-
tin/dalfopristin (0.4 mg/0.1 ml; Synercid; DSM
Pharmaceuticals, Inc., Greenville, NC), ceftazidime
(2.25 mg/0.1 ml) (Fortum; GlaxoSmithKline, Mexico
DF, Mexico), and dexamethasone (0.4 mg/0.1 ml)
(Alin, Chinoin, Mexico DF, Mexico) was injected
intravitreally.
A coagulase-negative Staphylococcus aureus strain that
was vancomycin resistant was identified through culture
analysis.
Four days after intravitreal injection, total remission of
pain and hypopion was observed (Figure 2). Vitreous
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final best-corrected visual acuity was 20/40.
Discussion
Infectious endophthalmitis treatment has evolved with
time. The condition was a common complication in the
pre-Listerian era and the cause of many disastrous out-
comes in intraocular surgery.
Now, although uncommon, endophthalmitis remains
one of the most feared complications of intraocular sur-
gery [1]. The gold standard of treatment has been the
intravitreal administration [2] of antibiotics over topical,
subconjunctival, or systemic routes.
Several modifications have been made to the combina-
tion of antibiotics given intravitreally before the causa-
tive agent is known. These modifications are mainly
based on retinal toxicity and bacterial susceptibility to
different antibiotics. The combination of antibiotics that
is currently preferred empirically includes vancomycin
and ceftazidime.
Vancomycin is a glucopeptide antibiotic that is active
against Gram-positive bacteria [4]. Ceftazidime, a third-
generation cephalosporine, is active against Gram-nega-
tive bacteria, especially enterobacteria.
Although vancomycin has not been overused and is
reserved as a third-line antibiotic against serious infec-
tions (for example, sepsis), certain staphylococci strains
have developed resistance [5]. This could be a potential
source of therapeutic failure in some cases of
endophthalmitis.
Q/D is a combination of two streptogramins: quinu-
pristin (a B streptogramin) and dalfopristin (an A
streptogramin) at a 30:70 ratio, respectively. The com-
bination acts as a rapid bactericide, except for its
action against Enterococcus faecium, which is less. The
combination has a prolonged antibiotic effect (up to 10
hours) for Staphylococcus aureus compared with other
antibiotics. Its spectrum of coverage includes Gram-
positive cocci, including strains that are resistant to
other antibiotics. Methicillin-sensitive and resistant
strains of Staphylococcus aureus are also covered by
Q/D.
The minimal inhibitory concentrations are 1 mg/ml or
less. To the best of our knowledge, no reports of ocular
toxicity exist [6]. Given this excellent anti-staphylococcal
profile, the absence of ocular toxicity reports, the pro-
longed antibacterial effects, and the fact that no vanco-
mycin was available at the time, we decided to treat the
patient with the antibiotic combination described. Q/D,
conversely, is a more recent antibiotic, which, theoreti-
cally, is less likely to induce the development of resistant
strains than is vancomycin. The pharmacokinetics and
pharmacodynamics of intravitreal Q/D have not yet
been studied.
Our patient exhibited an adequate response to the use
of intravitreal Q/D that was documented four days after
injection. This response is similar to that shown to van-
comycin. Notably, the use of the combination carries
with it the potential advantage that we could be fighting
strains that are resistant to vancomycin. Moreover, a
synergistic effect of the vancomycin-quinupristin/dalfo-
pristin combination has been documented against some
Gram-positive bacteria [7]. We believe that the favorable
outcome in our patient was achieved, in order of
decreasing importance, by the following factors: 1) Q/D;
2) vitrectomy, which removed infected vitreous strands;
and 3) dexamethasone, which limited the severity of
inflammation. Ceftazidime affects mainly Gram-negative
bacteria, so it probably did not play an important role in
controlling the infection process.
Figure 1 Endophthalmitis OD showing marked ciliary reaction,
hypopion, and corneal edema.
Figure 2 Hypopion and inflammation remission 4 days after
intravitreal antibiotic injection.
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Q/D is an expensive medication, and its cost may out-
weigh its benefit. Moreover, the intravitreal route of this
antibiotic is off-label for infectious endophthalmitis.
Conclusion
In conclusion, Q/D showed a positive outcome in this
case of infectious postoperative endophthalmitis caused
by Gram-positive bacteria. To the best of our knowl-
edge, this is the first report on the use of intravitreal
quinupristin/dalfopristin in infectious Staphylococcus
endophthalmitis. This report does not recommend Q/D
as a first-line choice for conventional treatment of infec-
tious endophthalmitis. Rather, we describe a positive
outcome in one case.
Patient’s perspective
I write the following to provide assistance to the case
report written about my operation. I have no medical
knowledge or background, so I only write from my own
perspective and experience. I arrived at the hospital with
severe eye pain and completely blurred vision in my
right eye a few days after my cataract surgery. I then
was told that a very bad infection had taken over my
eye. I was told that one of the specific antibiotics for
this type of infection was not available, but that a non-
approved one could be of benefit, so I agreed to be trea-
ted with the non-approved antibiotic via eye injection,
in combination with other drugs as well as a vitrectomy
surgery, which was performed subsequently. A few
hours later, the pain slowly decreased until I did not feel
it any more. My sight was still blurred for about a
month and a half, but it slowly came back. I still see
some little dots, but my vision seems okay now.
Consent
Written informed consent was obtained from the patient
for the treatment and the publication of this case report
and any accompanying images. A copy of the written
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